BioSpace News Archive

Cytrellis Biosystems today announced members of the Cytrellis leadership team will participate at the Canaccord Genuity CG MedTech Diagnostics and Digital Health & Services Forum.

PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedical company focused on meeting significant unmet needs for women worldwide.

Mainz Biomed N.V. announced the closing of its previously announced registered direct offering with several institutional investors to purchase $5.0 million of its ordinary shares and warrants to purchase ordinary shares.

Oncotelic Therapeutics, Inc. (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a developer of treatments for rare and orphan indications, including Parkinson’s Disease, PDAC, DIPG, and COVID-19, today announced financial results for the three months ended September 30, 2023 (“Q3 2023”) as compared to the three months ended September 30, 2022 (“Q3 2022”).

NeurAxis, Inc. announced receipt of CareFirst Blue Cross Blue Shield policy coverage for the mid-Atlantic region with 3.5 million lives.

FSD Pharma Inc. is pleased to announce that it has provided certain additional disclosure, by way of a Supplement dated November 15, 2023 to its Management Information Circular dated October 20, 2023.

IQVIA Holdings Inc. announced that its wholly-owned subsidiary, IQVIA Inc., priced an offering of $1,250 million in aggregate principal amount of senior secured notes due 2029, which was upsized due to strong demand.

Zymo Research announced today that the U.S. Food and Drug Administration (FDA) has cleared its DNA/RNA Shield™ SafeCollect™ Saliva Collection Kit as a Class II medical device for microbial nucleic acid storage and stabilization.

The Mark Foundation for Cancer Research announced 16 outstanding projects in its latest class of ASPIRE awards, granting more than $5 million for research that aims to answer key feasibility and proof-of-concept questions in an accelerated time frame, and scaling for impact based upon initial success.

Aprecia, a precision drug delivery company, has partnered with the research and development experts at Battelle to develop groundbreaking 3D printing platforms with the potential to transform the way medicines are developed, manufactured, distributed, and administered.